Elizabeth Ellis, NP
Family · Montgomery, ALNPI 1982213898
Payments from drug & device makers
Across 140 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$410
- Amgen$378
- AbbVie$327
- Acorda Therapeutics, Inc$176
- Biohaven Pharmaceuticals, Inc.$157
- Sumitomo Pharma America, Inc.$108
- plus $964 from 20 others
What the payments were for
- Speaking & faculty fees$1767%
- Food & beverage$2,34593%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 26 | $410 |
| Amgen | 20 | $378 |
| AbbVie | 25 | $327 |
| Acorda Therapeutics, Inc | 10 | $176 |
| Biohaven Pharmaceuticals, Inc. | 6 | $157 |
| Sumitomo Pharma America, Inc. | 6 | $108 |
| Convatec Inc. | 2 | $100 |
| Neurelis, Inc. | 1 | $85 |
| Ipsen Biopharmaceuticals, Inc | 3 | $72 |
| Acadia Pharmaceuticals Inc | 5 | $68 |
| Procept Biorobotics Corporation | 2 | $65 |
| Neurocrine Biosciences, Inc. | 4 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Biogen | 3 | $51 |
| Akcea Therapeutics, Inc. | 3 | $50 |
| Vertex | 2 | $49 |
| Melinta Therapeutics, LLC | 3 | $47 |
| Endo USA, Inc. | 2 | $40 |
| Lilly USA, LLC | 3 | $39 |
| Genentech USA, Inc. | 2 | $38 |
| Sobi, Inc | 2 | $30 |
| Greenwich Biosciences, Inc. | 2 | $30 |
| Purdue Pharma L.p. | 2 | $28 |
| Boston Scientific | 1 | $23 |
| Urogen Pharma, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
How this compares
$2,521 in reported general payments places this provider in the 80th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyzine Hcl | 15 | $571 |
| Diclofenac Sodium | 80 | $562 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 36 | $436 |
| Cephalexin | 24 | $298 |
| Buspirone Hcl | 20 | $287 |
| Doxycycline Monohydrate | 14 | $190 |
| Azithromycin | 12 | $56 |
| Methocarbamol | 14 | $37 |
| Sertraline Hcl | 11 | $30 |
Paid to pharmacies, not to this prescriber.
Other family in Montgomery
- Leigh LunaMontgomery$69K
- Brandy YoungMontgomery$27K
- Angela RaybornMontgomery$22K
- Ashley MorrowMontgomery$21K
- Jackie ShumateMontgomery$19K
- Katrina Jones HarrisMontgomery$18K
- Brittney BarberMontgomery$12K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.